COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.
The Emerging Techbio Company Appoints Dr. John Mumm as CSO Alongside Head of Platform Dr. Yambazi Banda to Decode the Molecular Underpinnings of Neuroimmune...
- A clean signal on player sentiment for publishers and developers, free from review bombing and unverified scoresNEW YORK and SAN FRANCISCO, June 11,...
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.
SHANGHAI, June 8, 2026 /PRNewswire/ -- On June 8, PATEO (02889.HK) disclosed a voluntary announcement, announcing that it has signed a tripartite strategic cooperation framework...
Ethics Committee Approval Received for Pivotal Study Intended to Support U.S. FDA Class II Submission for QuickScan™ Strep AVANCOUVER, BC, June 4, 2026 /CNW/...
The company highlights increasing retail interest in quantitative futures strategies as investors seek alternatives to traditional market approaches.LOS ANGELES, June 3, 2026 /PRNewswire/ --...
BEIJING, June 2, 2026 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WiMi) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology...